MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, is developing experiential and psychedlic-based therapies to treat addiction and mental illness. MindMed's core philosophy is that a coordinated effort from therapists, drug developers, and patients is needed to develop personalized, precision treatments for each individual patient. The company believes that symptom management is unacceptable and patient's deserve treatments that put an end to their mental afflictions. To this end, the company is developing a network of partnerships to share data and drive insights to develop breakthrough therapies in the quickly evolving industry of mental wellness.
